Blog
19 March, 2024
The health sector, essential for the well-being of the population and an economic engine for society
fundacionidis.com The ecosystem of the private healthcare sector transcends the field of healthcare and has an impact on society and on the productive sectors of the […]
7 March, 2024
There are 146 orphan drugs approved by the European Medicines Agency. Spain has only 81 in its catalogue. It has rejected funding for 25 and is […]
5 March, 2024
Research into new drugs for rare diseases has multiplied in recent years. In Spain, industry drives 90% of clinical trials for this type of disease. One […]
13 February, 2024
In a press release, the Andalusian Regional Government highlights the joint commitment of both entities to continue advancing in the promotion of R&D&I, following the meeting […]
8 February, 2024
Of the 1,944 clinical trials authorised in the European Union through the new European Information System, Spanish centres participated in 845, or 43% of the total. […]
6 February, 2024
The European Medicines Agency has thus identified nine oncology approvals for 2023. The arrival of new treatments is directly linked to the pharmaceutical industry’s commitment to […]
2 February, 2024
The Technological Platform for Innovative Medicines – whose Coordination Committee is made up of 10 representatives from the pharmaceutical industry and 10 representatives from public research […]
1 February, 2024
Farmaindustria welcomes the presentation by the Ministry of Health of the harmonised catalogue of genetic tests for the whole country. For this catalogue to become a […]
30 January, 2024
The US expert unpacked the data from his study on the relationship between pharmaceutical innovation and cancer mortality in Spain between 1999 and 2016 in a […]
15 January, 2024
Infectious diseases, neurological diseases, type 2 diabetes in children, oncology and cardiac disorders are just some of the areas that benefited from the innovation drive last […]
11 January, 2024
8 January, 2024
“We are the industrial area that invests the most in R&D, a productive and exporting engine”. larazon.es Developing and producing new medicines for society is both […]
21 December, 2023
The working group led by Farmaindustria holds a new meeting, with the participation of two new pharmaceutical companies. Farmaindustria.es The drive for clinical research in Primary […]
19 December, 2023
Of the €1.395 billion registered in 2022, 60% was devoted to clinical trial development. One out of every eight euros is already spent on basic and […]
11 December, 2023
Farmaindustria participates in the Medical Oncology, Haematology and Oncohaematology Pharmacy Congress ‘Building Bridges’, where data management in biomedical research was discussed. Farmaindustria.es “The proposed Regulation for […]
1 December, 2023
Farmaindustria’s CEO, Juan Yermo, participates in the conference ‘Towards a Comprehensive European Plan: Spain’s involvement with Rare Diseases’, organised by Feder in the Spanish Congress of […]
27 November, 2023
Farmaindustria presents the ‘Guide of good practice recommendations for the promotion of clinical research in Primary Care’, which will bring new treatment opportunities to patients in […]
21 November, 2023
The director of Farmaindustria’s Research Department participates in a round table on the regulation of this project held at the European Parliament Office in Madrid. “For […]
13 November, 2023
The Code of Conduct regulating the processing of personal data in clinical trials approved in 2022 makes it easier for companies and researchers to correctly comply […]
2 November, 2023
The director of Farmaindustria’s Access Department, Isabel Pineros, participates in the XVI International Congress on Rare Diseases: “In recent years we have seen great advances in […]
30 October, 2023
This is demonstrated by a recent study by Professor Frank R. Lichtenberg of Columbia University, which has just been published in the journal Value in Health. […]
24 October, 2023
On World Disease Day, which is celebrated on October 19, Farmaindustria remembers the importance of clinical trials, the previous step for the arrival of innovative treatments […]
17 October, 2023
The document proposes, without the need for a regulatory change, a procedure that would allow the equitable arrival of drugs that meet certain criteria that make […]
11 October, 2023
elglobal.es In a political context with elections called for the European Parliament at the beginning of June 2024 and with Spain holding the presidency of […]
9 October, 2023
Between 2020 and 2022, 446 clinical trials with children and adolescents were conducted in our country, almost half of them focused on rare diseases and 90.4% […]
4 October, 2023
In recent years, the number of applications capable of interacting with patients to prevent, manage or treat diseases has increased, and which can also generate data […]
2 October, 2023
The 7th Congress of Patients’ Organisations, organised by the POP, analyses the application of the new European Regulation on Clinical Trials. Farmaindustria’s director general, Juan Yermo, […]
26 September, 2023
The vast majority of them are aimed at modifying the course of the disease, according to an Iqvia report on the future of R&D. In Spain […]
19 September, 2023
Only 7.5% are carried out in health centres. In order to alleviate this situation, Farmaindustria has presented a programme to promote them in outpatient clinics. Source: […]
14 September, 2023
“We are going to create a favourable environment”. This statement by José Manuel Miñones is the first step towards a roadmap that would highlight the key […]
23 May, 2025
The XVIII Conference of Biomedical Research Technology Platforms brings together in Madrid more than 200 representatives from public administrations, regulatory agencies, universities and companies to analyse […]
22 May, 2025
Nathalie Moll (EFPIA) warns in an interview with Health35 that the lack of regulatory consistency and proposed environmental changes threaten investment in biomedical R&D in Europe. […]
21 May, 2025
In order to host the studies, the centres must have the resources and infrastructure. Gregorio Marañón, La Paz, Clínic de Barcelona and Vall d’Hebron are some […]
13 May, 2025
Farmaindustria presents improvements to the Draft Medicines Bill to prepare healthcare for innovation in the next 20 yearsThe future law should promote greater investment in healthcare, […]
12 May, 2025
“It is essential to see medicines and healthcare as an economically and socially very profitable investment for Spain. An investment that generates very important benefits in […]
8 May, 2025
eleconomista.es In 2023, Spain overtook Germany as the country that initiated the most clinical trials and became the European leader. This is reflected in the report […]
22 April, 2025
Joint position on the Draft Bill on Medicines and Health ProductsThe proposed system of price regulation for off-patent medicines puts at risk the supply of medicines […]
8 April, 2025
The International Federation of Innovative Pharmaceutical Industries indicates that the sector invests almost 30% of its revenues in R&D, amounting to nearly 270 billion euros. Diarofarma.com […]
18 March, 2025
The Regional Minister of Health of Cantabria, César Pascual, inaugurates the 25th CAAC-Pharmaindustry Forum. ‘When we work together, not only do we promote research and biomedical […]
6 March, 2025
This research momentum means that one in three new medicines approved by Europe in 2024 was classified as an orphan drug. There are still many untreated […]
4 March, 2025
Getting to know new markets and establishing contacts with both potential customers and potential suppliers. Temperature control in pharmaceutical logistics is one of our pillars, as […]
20 February, 2025
The President of the Government meets for the second time with around twenty representatives of the national, European and global pharmaceutical industry to intensify public-private collaboration […]
